The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices appears less eager than the White House to quickly clear COVID-19 boosters for all vaccinated Americans, throwing a potential wrench into the Biden administration’s goal of beginning to offer additional shots the week of 20 September.
CDC Vaccine Advisors Less Enthusiastic Than White House About Universal COVID Boosters
Focus should remain on primary vaccines and boosters for populations not protected from severe outcomes with initial vaccination, CDC advisors say, potentially contradicting Biden administration plans for widespread allowance of third COVID-19 shots. A booster authorization by the White House’s planned 20 September timeline would also compromise Pfizer’s ability to finish a placebo-controlled study evaluating the impact of its booster on clinical outcomes.
More from Vaccines
• By
Former Acting FDA Commissioner Sara Brenner is said to have asked Tracy Beth Høeg, new special assistant to the commissioner, to help reexamine the application. Høeg’s position at the agency is raising concerns about the FDA's ongoing approach to vaccine regulation.
• By
FDA Commissioner Martin Makary was sworn in Friday and knew of the plan that ultimately lead to CBER director Peter Marks' resignation on 28 March.
• By
In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."
• By
Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.
More from Pink Sheet
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.